Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 10;23(8):1997.
doi: 10.3390/molecules23081997.

Chemical Synthesis of Rare, Deoxy-Amino Sugars Containing Bacterial Glycoconjugates as Potential Vaccine Candidates

Affiliations
Review

Chemical Synthesis of Rare, Deoxy-Amino Sugars Containing Bacterial Glycoconjugates as Potential Vaccine Candidates

Archanamayee Behera et al. Molecules. .

Abstract

Bacteria often contain rare deoxy amino sugars which are absent in the host cells. This structural difference can be harnessed for the development of vaccines. Over the last fifteen years, remarkable progress has been made toward the development of novel and efficient protocols for obtaining the rare sugar building blocks and their stereoselective assembly to construct conjugation ready bacterial glycans. In this review, we discuss the total synthesis of a variety of rare sugar containing bacterial glycoconjugates which are potential vaccine candidates.

Keywords: bacterial glycoconjugates; rare deoxy-amino sugars; stereoselective glycosylation; total synthesis; vaccine candidates; zwitterionic polysaccharides.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Representative examples of rare deoxy amino monosaccharides present in bacteria.
Scheme 1
Scheme 1
Ito’s first-generation synthesis of the heptasaccharide from C. jejuni.
Scheme 2
Scheme 2
Glycosylation of C. jejuni hexasaccharide with bacillosamine.
Scheme 3
Scheme 3
Ito’s second-generation total synthesis of C. jejuni heptasaccharide.
Scheme 4
Scheme 4
Van der Marel’s assembly of protected tetrasaccharide repeating unit of zwitterionic polysaccharides (ZPS) A1.
Scheme 5
Scheme 5
First total synthesis of ZPS A1 by Seeberger and co-workers.
Scheme 6
Scheme 6
Kulkarni’s synthesis of the rare disaccharide donor unit of ZPS A1.
Figure 2
Figure 2
Structure of ZPS A1 with alternating charges on adjacent monosaccharides.
Scheme 7
Scheme 7
Bundle’s first total synthesis of Streptococcus pneumoniae ZPS trisaccharide.
Scheme 8
Scheme 8
Bundle’s total synthesis of Streptococcus pneumoniae ZPS hexasaccharide.
Scheme 9
Scheme 9
Codée’s synthesis of all the Streptococcus pneumoniae Sp1 ZPS trisaccharides.
Scheme 10
Scheme 10
Seeberger’s total synthesis of thioether linked S. pneumoniae Sp1 trisacharide.
Scheme 11
Scheme 11
Schmidt’s total synthesis of lipoteichoic acid of Streptococcus pneumoniae.
Figure 3
Figure 3
Structure of lipoteichoic acid of S.pneumoniae.
Scheme 12
Scheme 12
Seeberger’s total synthesis of capsular polysaccharides (CPS) repeating unit of S. pneumoniae Serotype 4.
Scheme 13
Scheme 13
Seeberger’s total synthesis of S. pneumoniae serotype 12F CPS repeating unit.
Scheme 14
Scheme 14
Seeberger’s synthesis of S. pneumoniae serotype 5 glycan.
Scheme 15
Scheme 15
Mulard’s total synthesis of ZPS of Shigella sonnei.
Scheme 16
Scheme 16
Kulkarni’s one-pot synthesis of ZPS of P. alcalifaciens O22.
Scheme 17
Scheme 17
Adamo’s first total synthesis of Staphylococcus aureus type 5 repeating unit.
Scheme 18
Scheme 18
Boons’ total synthesis of Staphylococcus aureus type 5 repeating unit.
Scheme 19
Scheme 19
Demchenko’s total synthesis of Staphylococcus aureus type 5 repeating unit.
Scheme 20
Scheme 20
Codée’s total synthesis of Staphylococcus aureus type 5 repeating unit.
Scheme 21
Scheme 21
Demchenko’s total synthesis of Staphylococcus aureus type 8 repeating unit.
Scheme 22
Scheme 22
Codée’s total synthesis of Staphylococcus aureus Strain M repeating unit.
Scheme 23
Scheme 23
Kulkarni’s total synthesis of DATDG containing pilin glycan of N. meningitidis.
Scheme 24
Scheme 24
Kulkarni’s total synthesis of Bac containing pilin glycan of N. meningitidis.
Scheme 25
Scheme 25
Kulkarni’s first total synthesis of Bacillus cereus Ch HF-PS.
Scheme 26
Scheme 26
Kulkarni’s total synthesis of glycan of Yersinia enterocolitica.
Scheme 27
Scheme 27
Kulkarni’s synthesis of P. chlororaphis subsp. aureofaciens strain M71 glycan.
Scheme 28
Scheme 28
Synthesis of P. shigelloides serotype 51 aminoglycoside trisaccharide antigen.
Scheme 29
Scheme 29
Li’s synthesis of Pseudomonas aeruginosa 1244 Pilin glycan.

Similar articles

Cited by

References

    1. Varki A. Biological Roles of Oligosaccharides: All of the Theories Are Correct. Glycobiology. 1993;3:97–130. doi: 10.1093/glycob/3.2.97. - DOI - PMC - PubMed
    1. Nishat S., Andreana P. Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses. Vaccines. 2016;4:19. doi: 10.3390/vaccines4020019. - DOI - PMC - PubMed
    1. Avci F.Y., Li X., Tsuji M., Kasper D.L. A Mechanism for Glycoconjugate Vaccine Activation of the Adaptive Immune System and Its Implications for Vaccine Design. Nat. Med. 2011;17:1602–1609. doi: 10.1038/nm.2535. - DOI - PMC - PubMed
    1. Micoli F., Costantino P., Adamo R. Potential Targets for next Generation Anti-Microbial Glycoconjugate Vaccines. FEMS Microbiol. Rev. 2018;42:388–423. doi: 10.1093/femsre/fuy011. - DOI - PMC - PubMed
    1. Dube D.H., Champasa K., Wang B. Chemical Tools to Discover and Target Bacterial Glycoproteins. Chem. Commun. 2011;47:87–101. doi: 10.1039/C0CC01557A. - DOI - PubMed

MeSH terms

LinkOut - more resources